Zusammenfassung
Trotz der Bedeutung der Spondylarthropathien im täglichen klinischen Alltag gibt es wenige etablierte Therapieansätze. Dieser Mangel ist vor allen Dingen frappierend bei der ankylosierenden Spondylitis, der häufigsten Erkrankung innerhalb der Spondylarthropathien, die auch den schwersten Verlauf aufzeigen kann. Sulfasalazin wirkt höchstens bei frühen Formen der ankylosierenden Spondylitis, während es bei der Manifestation einer peripheren Arthritis bei allen Formen der Spondylarthropathien wirksam ist. Die nahezu dramatische Besserung der Symptome bei späten Verlaufsformen der ankylosierenden Spondylitis unter einer Therapie mit dem TNFα-blockierenden Antikörper Infliximab zeigt neue Therapiewege auf und lässt durchaus Optimismus aufkommen, dass für diese chronisch-entzündliche Erkrankung Behandlungsansätze gefunden werden, ähnlich wie es sehr erfolgreich in der letzten Dekade für die rheumatoide Arthritis gelungen ist. Hierfür wird der Verbund innerhalb des Kompetenznetzes Rheuma in Deutschland eine wichtige Stütze sein.
Schlüsselwörter
Key words
Summary
Anti-TNF therapy seems to be highly effective in AS. Based on the available results, this treatment seems to be at least as effective as in RA. Furthermore, because no other treatments are available for AS — in contrast to RA or psoriatic arthritis — infliximab might even become a first-line immunosuppresive treatment in patients with severe, active AS. A dosage of 5 mg/kg seems to be required and intervals between 6–12 weeks seem to be necessary depending on the disease activity. It remains to be shown what the long-term effects are, whether the patients benefit from long-term therapy and whether radiological progression and ankylosis can be stopped. Allergy, lupus-like diseases and tuberculosis are rare side effects which need to be addressed. At first glance, the possible benefits of anti-TNF therapy seem to outweigh these shortcomings.
Schlüsselwörter
Key words
Preview
Unable to display preview. Download preview PDF.
Literatur
Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A et al (1998) Prevalence of spondylarthropathies in HLA B27-positive and -negative blood donors. Arthritis Rheum 41:58–67
Brandt J, Bollow M, Haberle J, Rudwaleit M, Eggens U, Distler A et al (1999) Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology (Oxford) 38:831–836
Gran JT, Husby G, Hordvik M (1985) Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 44:359–367
Saraux A, Guedes C, Allain J, Devauchelle V, Valls I, Lamour A et al (1999) Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l’Ouest. J Rheumatol 26: 2622–2627
Zink A, Listing J, Wollenhaupt J (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis-results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 27:613–622
Boonen A, Chorus A, Miederna H, van der Heijde D, van der Tempel H, van der Linden S (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60: 353–358
Amor B, Dougados M, Mijiyawa M (1990) [Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic 57:85–89
Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H et al (1999) Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 38:235–244
Dougados M, Behier JM, Jolchine I, Calin A, van der Heijde D, Olivieri I, Zeidler H et al (2001) Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 44:180–185
Dougados M, van der Linden S, Leiri-salo-Repo M, Huitfeldt B, Juhlin R, Veys E et al (1995) Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38:618–627
Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum 42:2325–2329
Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-Kerttula U (1988) Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum 31:1111–1116
Benitez-Del-Castillo JM, Garcia-Sanchez J, Iradier T, Banares A (2000) Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 14:340–343
Yamane K, Saito C, Natsuda H, Yuhara T, Akama T, Suzuki H et al (1993) Ankylosing spondylitis successfully treated with methotrexate. Intern Med 32:53–56
Creemers MC, Franssen MJ, van de Putte LB, Gribnau FW, van Riel PL (1995) Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol 22:1104–1107
Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM (2000) Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 19:114–117
Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM (2000) Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 29:160–162
Maksymowych WP, Jhangri GS, Leclercq S, Skeith K, Yan A, Russell AS (1998) An open study of Pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 25:714–717
Maksymowych WP, Lambert R, Jhangri GS, Leclerc S, Chiu P, Wong B et al (2001) Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous Pamidronate therapy. J Rheumatol 28:144–155
Breban M, Gombert B, Amor B, Dougados M (1999) Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum 42:580–581
Braun J, Lemmel M, Manger B, Rau R, Sörensen H, Sieper J (2001) Therapy of ankylosing spondylitis with Radiumchloride. Z Rheumatol 60:74–83
Braun J, Bollow M, Eggens U, Konig H, Distler A, Sieper J (1994) Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 37:1039–1045
Braun J, Bollow M, Sieper J (1998) Radiology and Pathology of the Spondyloarthropathies. Rheum Dis Clin N Am 24:697–735
McGonagle D, Gibbon W, O’Connor P, Green M, Pease C, Emery P (1998) Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 41:694–700
Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38:499–505
Francois RJ, Gardner DL, Degrave EJ, Bywaters EG (2000) Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum 43:2011–2024
Bollow M, Fischer T, Reißhauer H, Sieper J, Hamm B, Braun J (2000) T cells and macrophages predominate in early and active sacroiliitis as detected by magnetic resonance imaging in spondyloarthropathies. Ann Rheum Dis 59(2):135–140
Laloux L, Voisin MC, Allain J, Martin N, Kerboul L, Chevalier X, Audepierre P (2001) Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 60:316–321
Mielants H, Veys EM (1985) HLA B27-related arthritis and bowel inflammation: Sulfasalazine in HLA B27-related arthritis. J Rheumatol 12: 287–293
Sandborn WJ (1999) Anti-tumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm Bowel Dis 5:119133
Mease PJ, Goffe BS, Metz J, Vander-Stoep A, Finck B, Burge DJ (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 29,356:385–390
Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL et al (1997) Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75) -Fc Fusion Protein. N Engl J Med 337:141–148
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594–1602
Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J et al (1994) Successful treatment of active ankylosing spondylitis with the antitumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346–1352
Garrett S, Jenkinson TR, Kennedy LG, Whitelock HC, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis. The Bath AS disease activity index. J Rheumatol 21:2286–2291
Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM (2000) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59:428–433
Gorman JD, Sack KE, Davis JC (2000) Etanercept in the treatment of ankylosing spondylitis: a randomized, double-blind, placebo-controlled study. Arthritis Rheum 43:S403
Wilkinson NZ, Kingsley GH, Jones HW, Sieper J, Braun J, Ward ME (1999) The detection of DNA from a range of bacterial species in the joints of patients with a variety of arthritides using a nested, broad-range polymerase chain reaction. Rheumatology 38:260–266
Schnarr S, Putschky N, Jendro MC, Zeidler H, Hammer M, Kuipers JG, Wollenhaupt J. Chlamydiaand Borrelia-DNA in synovial fluid of patients with early undifferentiated oligoarthritis: results of a prospective study. Arthritis Rheum in press
Sieper J, Fendler C, Laitko S, Sorensen H, Gripenberg-Lerche C, Hiepe F, Alten R, Keitel W, Groh A, Uksila J, Eggens U, Granfors K, Braun J (1999) No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthritis Rheum 42:1386–1396
Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Mottonen T, Hakola M, Korpela M, Sanila M, Parviainen J, Uksila J, Vainionpaa R, Toivanen A (2000) Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis Jul 59(7):565–570
Lauhio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H (1991) Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 34:6–14
Dreses-Werringloer U, Padubrin I, Jürgens-Saathoff B, Hudson AP, Zeidler H, Köhler L (2000) Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicobial Agents Chemother 44: 3288–3297
Dreses-Werringloer U, Padubrin I, Zeidler H, Köhler L (2000) In vitro effect of azithromycin and rifampicin on chlamydial infection in epithelial HEp-2 cells. In: Saiku P (ed) Proceedings of the 4th meeting of the European Society for Chlamydia research. Universitas Helsingiensis, p 393
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Steinkopff Verlag
About this chapter
Cite this chapter
Sieper, J., Braun, J. (2002). Aktueller Stand der Therapieansätze bei Spondylarthropathien. In: Hein, G., Zeidler, H., Meznerits, I. (eds) Umsetzung neuer Therapien in der rheumatologischen Praxis und Versorgung. Steinkopff. https://doi.org/10.1007/978-3-642-85445-3_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-85445-3_6
Publisher Name: Steinkopff
Print ISBN: 978-3-7985-1334-1
Online ISBN: 978-3-642-85445-3
eBook Packages: Springer Book Archive